AMSTERDAM, Netherlands, Aug. 7, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, today announced recent key achievements and financial results for the second quarter and first half of 2008.
